Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders Portfolio News / By Karina Tin June 22, 2021
Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development Portfolio News / By Karina Tin June 21, 2021
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Portfolio News / By Karina Tin June 18, 2021
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Biology Conference: Fundamental Mechanisms and Translational Applications Portfolio News / By Karina Tin June 17, 2021
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI) Portfolio News / By Karina Tin June 16, 2021
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock Portfolio News / By Karina Tin June 15, 2021
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis Portfolio News / By Karina Tin June 14, 2021
Synthekine Announces $107.5 Million Oversubscribed Series B Financing to Support Lead Programs to Clinical Proof of Concept, Advance Preclinical Programs and Platform Portfolio News / By Karina Tin June 10, 2021
eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial Portfolio News / By Karina Tin June 9, 2021